Navigation Links
Esperance Pharmaceuticals Completes $7.5 Million Series B Financing
Date:6/1/2011

ion."

Esperance is using its CLYP™ technology to develop a robust portfolio of novel targeted membrane-disrupting peptides (tMDPs) to selectively destroy cancer cells that express target receptors. EP-100, the lead candidate, is designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces and is currently in a Phase 1 study in patients with advanced solid tumors. LHRH receptors are over-expressed in a wide range of human cancers including breast, prostate, endometrial, pancreatic, ovarian, skin, testicular and blood cancers. In addition to EP-100, Esperance has other drug candidates in preclinical stages of development, all of which have a unique targeting mechanism of action whereby candidates bind specifically and exclusively to surface antigens or receptors on cancer cells.

About Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is a clinical stage company developing a new class of targeted anticancer drugs using its Cationic Lytic Peptide (CLYP™) platform technology. These drug candidates, called targeted membrane-disrupting peptides (tMDPs) and antibody drug conjugates (ADCs) selectively seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. Targeting occurs through binding to specific receptors and antigens on the cell's surface. The Company was founded on patented technology discovered by scientists at the Pennington Biomedical Research Center, the Louisiana State (LSU) Ag Center and LSU main campus. Founding investors include the Louisiana Fund I, Themelios Ventures and Research Corporation Technologies. Additional investors include Sanofi, Advantage Capital Partners/Louisiana Technology Fund and private investors. More information can be found at www.esperancepharma.com.


'/>"/>
SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Conn. , Aug. 27, 2014  UBM Medica ... a leading online community for medical imaging professionals, presents ... Association for Medical Imaging Management,s 2014 Annual Meeting . ... conference coverage: , 11 Principles of ... can lead to greater profitability. , Why ...
(Date:8/27/2014)... 2014 Ambit Biosciences (Nasdaq: AMBI ), a ... unmet needs in oncology, autoimmune and inflammatory disease, today announced ... to be held at The New York Palace Hotel in ... 2014. Alan Fuhrman , Ambit,s CFO, will ... candidate, quizartinib, at 1:10 p.m. ET on Wednesday, September 3, ...
(Date:8/27/2014)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... scheduled to make an investor presentation at the Robert W. ... on Wednesday, September 3, in New York City.  ... be available in the Investors section of the IRIDEX website ... IRIDEX Corporation was founded in 1989 and is a ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Ambit Announces Participation At Baird 2014 Health Care Conference 2
... December 13, 2011 -- Breadth of ... Pieris AG presented novel preclinical in ... its PRS-080 Anticalin hepcidin antagonist in an oral presentation ... company announced today.  In a presentation entitled "Discovery and ...
... 13, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ: ... Ltd. announced that final results from the phase II ... or refractory acute myeloid leukemia (AML) were presented by ... Anderson Cancer Center during the Acute Myeloid Leukemia - ...
Cached Medicine Technology:Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 2Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... especially when your infant looks at you and babbles. ... by listening and responding, they let their infants know ... sounds and using language more quickly. , That,s according ... and Indiana University that found how parents respond to ... communicate and use vocalizations. , The findings challenge the ...
(Date:8/27/2014)... For nearly two decades, audiences around the world ... Deva Premal & Miten with their rapturous Nepali flute ... album in May, their 2014 MANTRAS FOR LIFE TOUR ... globe, including Russia, Ukraine, Israel, Australia, the U.S., Canada, ... new album and a new five-piece band, the love ...
(Date:8/27/2014)... 27, 2014 The American Brain ... of the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery ... the ABTA is seeding the field with talented, bright ... understanding of the causes, effects, diagnosis and treatment of ... scientific committee based on the potential to advance the ...
(Date:8/27/2014)... While many scientists are trying to prevent the ... autophagy, researchers at Virginia Commonwealth University Massey Cancer ... that causes the process to culminate in cell ... targets the p62 protein, which is often referred ... role in disposing unwanted cellular proteins during autophagy. ...
Breaking Medicine News(10 mins):Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2Health News:Parents, listen next time your baby babbles 2Health News:Parents, listen next time your baby babbles 3Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2
... already known to predict heart disease may also indicate ... a new Johns Hopkins study. ,C-reactive protein, or ... of CRP have been linked to higher risks of ... and diabetes. Researshers hypothesized that inflammation could play a ...
... legs syndrome is an irritating feeling of uneasiness, tiredness and ... can be painful // and often worsen at night. ... called restless legs syndrome. Studies on restless legs syndrome are ... to look at the prevalence and factors related to restless ...
... source of radiation exposure to the general population. Although ... also believed exposure during the test is responsible for ... to calculate the risk of cancer from exposure to ... and Cancer Research in the United Kingdom conducted the ...
... blood may predict the risk of heart attack or death ... new study. ,Researchers conducted a study to determine whether ... for death or non-fatal heart attack in patients with acute ... factor family and it acts as an instigator of hardening ...
... cancer accounts for the largest number of new cancer ... an international study found the survival rate of non-small-cell ... adjuvant chemotherapy. Cisplatin is an anti-neoplastic medication that interferes ... growth and spread in the body. ,As ...
... percent of diabetics take the proper preventative measures ... Researchers stressed continued negligence by diabetics increases their ... coronary heart disease, stroke, and lower extremity amputations. ... years or older, who had been diagnosed with ...
Cached Medicine News:Health News:Blood Marker Found To Predict Colon Cancer 2
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Medicine Products: